Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
193 Clinical Trials near Allen, TX
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerInclisiran for Cardiovascular Disease
Plano, Texas
VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthcare Systems (HCS) to systematically identify those at high risk for and already diagnosed with ASCVD for more expeditious achievement of LDL-C targets.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Pregnancy, Heart Failure, Arrhythmia, Others
Must Be Taking:Statins
1440 Participants Needed
Baricitinib for Rheumatoid Arthritis
Allen, Texas
This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Cancer, Active Tuberculosis, Serious Infection, Others
Must Be Taking:DMARDs
1300 Participants Needed
EYE103 for Macular Degeneration
Plano, Texas
EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of EYE103 via IVT or a high dose of EYE103 via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion.
All participants in the study will receive a total of 3 injections of EYE103 into the study eye, spaced at 4 weeks apart. All participants will return at designated time points following each injection for safety and efficacy assessments. The Week 12 Visit will serve as the end of study visit for all participants.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Cataract Surgery, Others
Must Not Be Taking:Retinal Toxicity Drugs
160 Participants Needed
BI 771716 for Age-Related Macular Degeneration
Plano, Texas
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy.
In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye.
Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50+
Key Eligibility Criteria
Disqualifiers:Exudative AMD, Uncontrolled Glaucoma, Others
188 Participants Needed
EYE201 for Eye Conditions
Plano, Texas
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201.
All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4 weeks apart.
In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE201 will be assessed at increasing doses in branch retinal vein occlusion (BRVO) participants. Approximately 12 participants will be entered in this part of the study.
In the second part of the study, called the dose finding part, 2 doses of EYE201 will be selected and their effectiveness will be compared. This portion of the study assesses the safety and preliminary efficacy of EYE201 in patients with diabetic macular edema (DME) or neovascular macular degeneration (NVAMD). Approximately 80 participants will be entered in this part of the study.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Blood Pressure, Others
92 Participants Needed
Ianalumab for Systemic Sclerosis
Allen, Texas
The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Rheumatic Disease, Pulmonary Disease, Others
Must Not Be Taking:Cyclophosphamide, Biologics, Anti-fibrotics, Others
200 Participants Needed
MANP for High Blood Pressure
Plano, Texas
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Secondary Hypertension, Recent MI, CHF, Others
Must Be Taking:Antihypertensives, Diuretics, ACEi Or ARB
120 Participants Needed
RE104 for Postpartum Depression
Plano, Texas
This trial is testing whether a single injection of RE104 can help reduce depression in women who have moderate-to-severe postpartum depression. The goal is to see if this treatment works effectively. The exact way RE104 works isn't detailed, but it likely helps by affecting brain chemicals related to mood.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 45
Sex:Female
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Psychosis, Others
Must Be Taking:SSRIs
72 Participants Needed
Tovinontrine for Heart Failure
McKinney, Texas
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Recent HF Exacerbation, Acute Coronary Syndrome, Others
Must Be Taking:Guideline-directed HF Therapy
557 Participants Needed
Tovinontrine for Heart Failure
McKinney, Texas
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Recent HF Exacerbation, Acute Coronary Syndrome, Others
Must Be Taking:Guideline-directed HF Therapy
303 Participants Needed
Rosnilimab for Rheumatoid Arthritis
Plano, Texas
This trial is testing Rosnilimab, a new medication, to see if it can help people with moderate to severe rheumatoid arthritis by reducing joint pain and swelling. The study will check if the medication is safe and effective.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Inflammatory Joint Disease, Cancer, Others
Must Be Taking:CsDMARDs
420 Participants Needed
This trial is testing a new drug, TRK-950, combined with two existing cancer drugs in patients with a specific type of stomach cancer. The goal is to see if this combination can better control cancer growth and improve survival compared to the existing treatments alone.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Congestive Heart Failure, Pneumonitis, Others
Must Be Taking:Ramucirumab, Paclitaxel
146 Participants Needed
TTI-101 for Idiopathic Pulmonary Fibrosis
McKinney, Texas
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40+
Key Eligibility Criteria
Disqualifiers:Respiratory Infections, Surgery, Cardiac Disorders, Others
Must Be Taking:Nintedanib
75 Participants Needed
IMVT-1402 for Sjogren's Syndrome
Allen, Texas
This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Rheumatoid Arthritis, Lupus, Fibromyalgia, Others
180 Participants Needed
Targeted Therapies for Rheumatoid Arthritis
Plano, Texas
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA).
This study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab monotherapy compared to placebo and Substudy 3 will evaluate lutikizumab and ravagalimab combination therapy (treatments given together) compared to placebo. Approximately 180 participants who have failed 1 or 2 biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies will be enrolled in the study at approximately 65 sites worldwide.
There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Juvenile Arthritis, Other Joint Diseases
Must Be Taking:Methotrexate
180 Participants Needed
IMVT-1402 for Rheumatoid Arthritis
Allen, Texas
This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Active Malignancy, Immunodeficiency, Others
Must Not Be Taking:Rituximab, Anti-FcRn
120 Participants Needed
mRNA-1195 for Multiple Sclerosis
Plano, Texas
The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 55
Key Eligibility Criteria
Disqualifiers:Fever, Unstable Condition, Myocarditis, Others
Must Not Be Taking:Systemic Immunosuppressants
180 Participants Needed
Obexelimab for Multiple Sclerosis
Plano, Texas
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 60
Key Eligibility Criteria
Disqualifiers:Primary Progressive MS, Neuromyelitis Optica, Others
93 Participants Needed
Abiprubart for Sjögren's Syndrome
Plano, Texas
Primary objective of the study is to evaluate the effect of abiprubart on an established systemic disease activity measure for Sjögren's Disease.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Fibromyalgia, Immunodeficiency, Thromboembolic, Others
Must Not Be Taking:Injectable Corticosteroids
200 Participants Needed
BHV-7000 for Epilepsy
Plano, Texas
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Ongoing Adverse Events, Others
660 Participants Needed
Why Other Patients Applied
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
BHV-7000 for Depression
Plano, Texas
This trial is testing a new medication called BHV-7000 to see if it is safe and well-tolerated over several months in people with Major Depressive Disorder. The goal is to help those who suffer from severe depression by potentially offering a new treatment option.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Medical Condition, Non-compliance, Risk To Others
480 Participants Needed
Itepekimab for Bronchiectasis
Plano, Texas
ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive).
Study details include:
* The study duration (screening, 24-52-week treatment, 20-week safety follow-up) will be up to 47-77 weeks.
* The treatment duration will be up to 24-52 weeks.
* The follow-up duration will be 20 weeks.
* Site/phone visits are at a monthly interval.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Cystic Fibrosis, Immunodeficiency, Tuberculosis, Autoimmune, Others
Must Not Be Taking:Antimicrobials, Immunosuppressants
312 Participants Needed
Verekitug for Severe Asthma
McKinney, Texas
This trial tests a new injectable medication, verekitug (UPB-101), on adults with severe asthma to see if it can reduce asthma attacks and improve breathing.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Recent Hospitalization, Smoking, Infections, Others
Must Be Taking:Inhaled Corticosteroids
479 Participants Needed
Verekitug for Nasal Polyps
McKinney, Texas
This trial tests a new injectable medication, verekitug (UPB-101), for people with chronic rhinosinusitis and nasal polyps who are already using nasal sprays. The goal is to see if it can shrink the polyps and improve symptoms.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Asthma, Sinus Surgery, Cardiac Disease, Others
Must Be Taking:Mometasone Furoate
70 Participants Needed
BMF-219 for Type 1 Diabetes
McKinney, Texas
This trial tests BMF-219, an oral medication that blocks a protein called menin, in people with Type 1 Diabetes. The goal is to see if it can help their insulin-producing cells work better and improve how their bodies handle sugar and fats.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:MODY, T2D, Cardiovascular Disease, Others
Must Be Taking:Insulin
37 Participants Needed
SAR443765 for Asthma
Plano, Texas
This trial tests an injectable medication called SC lunsekimig in adults aged 18 to 80 with moderate-to-severe asthma. The medication aims to reduce lung inflammation and open airways, helping patients breathe more easily.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:COPD, Smoking, Tuberculosis, Others
Must Be Taking:ICS Therapy
685 Participants Needed
mRNA Vaccine for Respiratory Syncytial Virus
Plano, Texas
This trial is testing a new vaccine called mRNA-1345 to protect young children and high-risk older children from RSV. The vaccine works by teaching the immune system to recognize and fight the virus. mRNA-1345 is among the most promising RSV vaccines, leveraging the success of mRNA technology seen in COVID-19 vaccines.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:2 - 17
Key Eligibility Criteria
Disqualifiers:Acute Illness, Recent Vaccines, Others
Must Not Be Taking:Immunosuppressants, RSV Antibodies
346 Participants Needed
INS018_055 for Idiopathic Pulmonary Fibrosis
McKinney, Texas
This trial tests a new oral medication, INS018_055, in adults with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the medication is safe and well-tolerated over a few months.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+
Key Eligibility Criteria
Disqualifiers:Acute IPF Exacerbation, Smoking, Pregnancy, Others
Must Be Taking:Antifibrotics
40 Participants Needed
EDP-938 for Respiratory Syncytial Virus
McKinney, Texas
This trial tests an oral medication called EDP-938 for adults with RSV who are at high risk of severe illness. The goal is to help fight the virus or reduce its impact.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:COPD, HIV, Hepatitis, Others
Must Not Be Taking:Antivirals, Antibacterials
180 Participants Needed
Emraclidine for Schizophrenia
Plano, Texas
This trial aims to evaluate the safety and tolerability of a medication called emraclidine, taken by mouth, in adults with schizophrenia.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Cardiovascular, Diabetes, Others
Must Be Taking:Antipsychotics
850 Participants Needed
Know someone looking for new options?
Spread the word